New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
07:12 EDTOREXOrexigen reports Q2 EPS (21c), consensus (21c)
Reports Q2 revenue $857K, consensus $1K
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
09:23 EDTOREXOn The Fly: Pre-market Movers
HIGHER: EMC Corporation (EMC), up 3.3% after announcing that it will be acquired by Dell... Esperion (ESPR), up 16.2% after Eli Lilly (LLY) said that it will discontinue development of evacetrapib... Orexigen Therapeutics (OREX), up 6.7% after Baupost reported a 17.17% passive stake in the company... Radius Health (RDUS), up 4.2% after reporting top-line Phase 3 data on abaloparatide for osteoporosis... Fiat Chrysler (FCAU), up 2.1% after announcing launch of Ferrari IPO... Tesla (TSLA), up marginally after Elon Musk tweeted software with Autopilot goes to wide release on Thursday. LOWER: Eli Lilly, down 9.1% after announcing that it will discontinue development of Evacetrapib due to insufficient efficacy... Magnum Hunter (MHR), down 39.5% after suspending monthly preferred dividends... Twitter (TWTR), down following reports of layoffs and halting the expansion of the company's headquarters.
October 9, 2015
16:17 EDTOREXBaupost reports 17.17% passive stake in Orexigen
Subscribe for More Information
October 6, 2015
06:51 EDTOREXOrexigen price target lowered to $11 from $21 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for Orexigen shares to $11 saying traction for Contrave, while good, is slightly below his expectations. He continues to view Contrave as a "novel asset" with large market potential of $700M in annual revenue, however. Duncan views the company's current market capitalization of $270M as a "market inefficiency" relative to the potential of the Contrave franchise. Duncan reiterates an Overweight rating on Orexigen.
October 1, 2015
08:46 EDTOREXOrexigen announces submission of Contrave NDA in South Korea
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use